Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | SPR | P35270 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139653 | 0.89 | RAB9A (0.63) | HSD11B1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL17891160 | 0.89 | RAB9A (0.63) | HSD11B1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL27888979 | 0.85 | KCNH2 (0.73) | KCNH2HRH3HSD11B1IDO1NPC1 | |
| SCHEMBL1531725 | 0.85 | KCNH2 (0.59) | KCNH2HRH3HSD11B1IDO1NPC1 | |
| SCHEMBL16963363 | 0.84 | CCR1 (0.57) | KCNH2HSD11B1IDO1NPC1RAB9A | |
| Hydrogen Sulfide SCHEMBL27863722 | 0.83 | KCNH2 (0.58) | KCNH2HRH3HSD11B1IDO1NPC1 | |
| SCHEMBL5490962 | 0.81 | KCNH2 (0.56) | KCNH2HRH3HSD11B1IDO1NPC1 | |
| SCHEMBL11123314 | 0.81 | KCNH2 (0.56) | KCNH2HRH3HSD11B1IDO1NPC1 | |
| SCHEMBL1473424 | 0.81 | QDPR (0.61) | KCNH2HRH3HSD11B1NPC1RAB9A | |
| SCHEMBL8903163 | 0.81 | YAP1 (0.58) | KCNH2HRH3HSD11B1IDO1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3737361-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | Centaurus Therapeutics (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| EP-2102214-B1 | 4, 5, 6, 7-TETRAHYDRO-THIENO [3, 2-C] PYRIDINE DERIVATIVES AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| CN-101547926-A | 4, 5, 6, 7-tetrahydro-thieno [3, 2-c] pyridine derivatives as H3 modulators | HOFFMANN LA ROCHE (CH) | 2009-09-30 | — | — | CN | disclosed |
| EP-2102214-A1 | 4, 5, 6, 7-TETRAHYDRO-THIENO [3, 2-C] PYRIDINE DERIVATIVES AS H3 MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| US-7557101-B2 | 4,5,6,7-tetrahydro-thieno[3,2-c] pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2008068173-A9 | 4, 5, 6, 7-TETRAHYDRO-THIENO [3, 2-C] PYRIDINE DERIVATIVES AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-20080146558-A1 | 4,5,6,7-Tetrahydro-Thieno [3,2-C] Pyridine Derivatives | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008068173-A1 | 4, 5, 6, 7-TETRAHYDRO-THIENO [3, 2-C] PYRIDINE DERIVATIVES AS H3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | KCNH2 4573/4885HRH3 1382/4885HSD11B1 594/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | KCNH2 1756/4885HRH3 861/4885HSD11B1 517/4885 |
| US-20080146558-A1 | 4,5,6,7-Tetrahydro-Thieno [3,2-C] Pyridine Derivatives | HRH4, HRH3, HRH2 | KCNH2 577/4885HRH3 2/4885HSD11B1 1042/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | KCNH2 4573/4885HRH3 1382/4885HSD11B1 594/4885 |
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | KCNH2 3856/4885HRH3 93/4885HSD11B1 1231/4885 |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | KCNH2 4573/4885HRH3 1382/4885HSD11B1 594/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | KCNH2 4573/4885HRH3 1382/4885HSD11B1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.